Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, im going to discuss my 3 worst stock market picks based on the mistakes I've made and what I learned from them.

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
10 Aug 2025, 17:23 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, im going to discuss my 3 worst stock market picks based on the mistakes I've made and what I learned from them.
Source overview

AI-generated source summary

The analysis focuses on three stocks (UNH, WALMEX and MUSA), providing insight on investment mistakes. The first stock discussed is UnitedHealth Group (UNH). The analyst bought UnitedHealth at $420 per share. The current share price is $244.67, representing a 41% decline. It is suggested investors need a catalyst for growth and may need a President to endorse stocks before people buy. For Wal-Mart de Mexico (WALMEX), a 6% loss after the stock price remained stagnant over five years. For Murphy USA(MUSA), the investors didn't focused on quality. AutoZone (AZO) was a better option but was more expensive than MUSA, which currently trades around $377. Inferred targets are also provided.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
2
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
50%
2 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  4. Market predictions extracted

    2 eligible signals linked to this case.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.2
Tracked signals
341
Historical success
33.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail